Chronic Myeloproliferative Disorders Completed Phase 1 Trials for Cyclophosphamide (DB00531)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00004904Stem Cell Transplantation in Treating Patients With Hematologic CancerTreatment
NCT00054236Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic AnemiaTreatment
NCT00080925T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic MalignanciesTreatment
NCT00255710Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic CancerSupportive Care
NCT00293410Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative DisordersTreatment